更新于：2024-12-12
Oseltamivir Phosphate
磷酸奥司他韦
更新于：2024-12-12
概要
基本信息
药物类型 小分子化药 |
别名 (−)-oseltamivir、1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-、Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate + [30] |
作用机制 neuraminidase抑制剂(神经氨酸苷酶抑制剂) |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1999-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H31N2O8P |
InChIKeyPGZUMBJQJWIWGJ-ONAKXNSWSA-N |
CAS号204255-11-8 |
关联
304
项与 磷酸奥司他韦 相关的临床试验The Effect of Fumarate Oseltamivir Injection on Psychomotor Recovery in Day Surgery Patients: A Randomized, Double-Blind, Parallel-Controlled Multicenter Clinical Tria
江西泰吉立生物医药科技有限公司持有的磷酸奥司他韦胶囊（规格：75 mg）与持证商为Roche Pharma (Schweiz) AG的磷酸奥司他韦胶囊（达菲®/Tamiflu®，75 mg）在中国健康受试者中进行的随机、开放、单剂量、两周期、双交叉、空腹及餐后状态下的生物等效性研究
磷酸奥司他韦胶囊的人体生物等效性试验
100 项与 磷酸奥司他韦 相关的临床结果
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的转化医学
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的专利（医药）
登录后查看更多信息
4,579
项与 磷酸奥司他韦 相关的文献（医药）2025-03-01BIOMATERIALS
Dynamic monitoring of a 3D-printed airway tissue model using an organic electrochemical transistor
Article
作者: Jung, Sungjune ; Lee, Yongwoo ; Owens, Róiśin M. ; Owens, Róisín M ; Kim, Woojo ; Chai, Seungjin ; Owens, Róisín M. ; Lee, Hwa-Rim ; Lee, Yunji
Assessing the transepithelial resistance to ion flow in the presence of an electric field enables the evaluation of the integrity of the epithelial cell layer. In this study, we introduce an organic electrochemical transistor (OECT) interfaced with a 3D living tissue, designed to monitor the electrical resistance of cellular barriers in real-time. We have developed a non-invasive, tissue-sensing platform by integrating an inkjet-printed large-area OECT with a 3D-bioprinted multilayered airway tissue. This unique configuration enables the evaluation of epithelial barrier integrity through the dynamic response capabilities of the OECT. Our system effectively tracks the formation and integrity of 3D-printed airway tissues in both liquid-liquid and air-liquid interface culture environments. Furthermore, we successfully quantified the degradation of barrier function due to influenza A (H1N1) viral infection and the dose-dependent efficacy of oseltamivir (Tamiflu®) in mitigating this degradation. The tissue-electronic platform offers a non-invasive and label-free method for real-time monitoring of 3D artificial tissue barriers, without disturbing the cellular biology. It holds the potential for further applications in monitoring the structures and functions of 3D tissues and organs, significantly contributing to the advancement of personalized medicine.
2025-02-01BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Synthesis and evaluation of anti-Giardia activity of oseltamivir analogs
Article
作者: VanKoten, Harrison W ; Patterson, Steven E. ; Pence, Breanna C ; Klinkenberg, James R. ; Patterson, Steven E ; VanKoten, Harrison W. ; Pence, Breanna ; Das, Siddhartha ; Klinkenberg, James R
We reported earlier that oseltamivir (Osm, Tamiflu®), an anti-viral agent, inhibits the attachment of trophozoites to intestinal epithelial cells and cyst production in culture. Osm also disassembles lipid rafts (LRs) and the biogenesis of extracellular vesicles (EVs) by Giardia. In the current study, we synthesized forty-one Osm analogs with the derivatization of oseltamivir phosphate. These compounds were tested on giardial growth, and cyst production. Of these, four analogs, i.e., compounds 3b, 2c, 11i, and 11d, were found to have superior activities against trophozoites and cysts compared to the parent oseltamivir. Investigation of the mechanism(s) of action of these agents are in progress and will be reported in due course.
2025-02-01JOURNAL OF ETHNOPHARMACOLOGY
Synergistic effects of Lianhuaqingwen in combination with Oseltamivir and Baloxavir against seasonal influenza virus: In vitro and in vivo assessment
Article
作者: Duan, Xuefeng ; Li, Xuanxuan ; Du, Han ; Bi, Yuhai ; Zhang, Cheng ; Yang, Jing ; Qi, Hui ; Rong, Wenwan ; Ma, Zhenghai ; Yuan, Manhua ; Li, Jianxiong ; Ji, Tiannan ; Zhang, Ning ; Dai, Bo
ETHNOPHARMACOLOGICAL RELEVANCE:
Lianhuaqingwen (LH), a traditional Chinese medicine, presents a broad-spectrum antiviral effect and has been widely used to treat influenza. Given the potential rise of drug-resistant influenza viruses, it is necessary to develop new antiviral drugs and explore combination therapies involving LH in tandem with existing antivirals such as Oseltamivir acid (Osel) or Baloxavir (Bal). These multidrug combinations could help effectively control the seasonal influenza epidemics and reduce the disease burden.
AIM OF THE STUDY:
This study aimed to evaluate the antiviral effects of LH, alone and in combination with Osel or Bal, against human seasonal influenza viruses in vitro and in vivo models.
MATERIALS AND METHODS:
The antiviral efficacy of LH alone and LH in combination with Osel/Bal against seasonal influenza A viruses (IAVs) (H1N1 and H3N2 subtypes) and influenza B viruses (IBVs) (BV- and BY-lineages) was assessed in vitro using MDCK cells. The median effective concentration (EC50) was determined, and the drug synergies were analyzed. Additionally, the antiviral activity of LH monotherapy and LH + Osel/Bal combination therapy were evaluated in vivo using an H1N1-infected BABL/c mouse model by monitoring changes in body weight, survival rate, lung viral titer, pathological damage, and inflammatory reaction.
RESULTS:
In vitro, LH alone and in combination with Osel/Bal exhibited antiviral activity against both IAVs and IBVs. The addition of LH to Osel/Bal improved the therapeutic efficacy compared to Osel/Bal alone. In vivo, LH monotherapy reduced body weight loss and increased the survival rates of H1N1-infected mice. LH in combination with Osel/Bal resulted in lower virus titers, more effective relief of pathological damage, and comparable low expression of inflammatory factors in the lungs of H1N1-infected mice compared to the use of Osel/Bal alone. Transcriptomic analysis of the lungs revealed that LH + Osel/Bal significantly increased the expression of genes associated with antiviral and anti-inflammatory effects.
CONCLUSIONS:
This study evaluated the antiviral effects of LH monotherapy and combination therapy with Osel/Bal against human seasonal influenza viruses in vitro and in vivo models. The results suggest that combining LH with Osel or Bal could enhance the antiviral efficiency for influenza viruses compared to the monotherapy using any of these three drugs.
837
项与 磷酸奥司他韦 相关的新闻（医药）2024-12-11
抗体药物偶联物细胞疗法免疫疗法引进/卖出蛋白降解靶向嵌合体
2024-12-08
·信狐药迅
疫苗信使RNA申请上市临床申请临床1期
2024-12-08
·信狐药迅
100 项与 磷酸奥司他韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 美国 | 1999-10-27 | |
| 流感病毒感染 | 瑞士 | 1999-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肥胖 | 临床2期 | 美国 | 2010-07-01 | |
| 慢性呼吸道疾病 | 临床1期 | 中国 | 2022-05-27 | |
| 糖尿病 | 临床1期 | 中国 | 2022-05-27 | |
| 心脏病 | 临床1期 | 中国 | 2022-05-27 | |
| 肾功能不全 | 临床1期 | 中国 | 2022-05-27 | |
| 乙型流感病毒感染 | 临床1期 | 中国 | 2021-09-06 | |
| 终末期肾脏病 | 临床1期 | 新西兰 | 2001-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 59 | 3-day prophylaxis with oral oseltamivir | 襯築鹽艱鬱衊糧壓鹹願(鹹顧窪構鹹遞網製糧廠) = 網齋遞蓋膚鹽網積製蓋 鬱鏇壓衊願積鑰鏇艱糧 (築襯鹽淵憲鏇積構齋網, 87.7 ~ 100) | 积极 | 2024-06-20 | ||
7-day prophylaxis with oral oseltamivir | 襯築鹽艱鬱衊糧壓鹹願(鹹顧窪構鹹遞網製糧廠) = 願衊鹹範遞憲獵鏇鬱遞 鬱鏇壓衊願積鑰鏇艱糧 (築襯鹽淵憲鏇積構齋網, 78.6 ~ 99.2) | ||||||
N/A | - | - | 憲壓鬱壓願壓淵簾繭網(壓艱廠齋構膚襯鬱餘膚) = Sialylation of platelets and leukocytes was markedly decreased in the proband compared with the healthy controls 簾艱艱鏇觸窪廠蓋淵簾 (鹽鏇窪遞淵襯淵積鑰餘 ) | - | 2021-07-17 | ||
N/A | - | Double-dose oseltamivir | 醖製觸艱鹽糧積齋鏇鹹(齋範積夢顧遞糧糧窪蓋): OR = 1.29 (95% CI, 0.52 ~ 3.15) 更多 | - | 2020-10-01 | ||
Standard-dose oseltamivir | |||||||
N/A | 82 | 憲壓積餘築積膚願顧窪(簾鹽鹹衊鬱鬱築構選壓) = There was no significant difference in the ICU admission rates 觸範鏇壓糧遞壓築蓋膚 (獵鏇蓋築構餘蓋構齋遞 ) 更多 | 不佳 | 2020-09-07 | |||
N/A | 222 | 5-day postexposure prophylaxis with oseltamivir | 製鑰糧餘鬱獵餘齋醖繭(鬱襯壓鑰夢顧製繭壓網) = 構選簾憲製夢鑰窪選繭 簾夢範選醖夢獵鹹構鏇 (衊製憲艱襯構鑰鬱廠獵 ) | - | 2020-08-01 | ||
N/A | 558 | Oseltamivir 75 mg | 顧積繭遞觸醖顧廠鑰遞(窪糧鹹糧願蓋遞築淵淵) = 憲淵獵糧築簾鏇糧糧獵 製製鹹淵醖網構簾顧淵 (選窪願蓋築鹹鬱鹽鑰艱 ) | - | 2020-05-23 | ||
Placebo | 顧積繭遞觸醖顧廠鑰遞(窪糧鹹糧願蓋遞築淵淵) = 簾窪襯繭鏇製簾艱膚憲 製製鹹淵醖網構簾顧淵 (選窪願蓋築鹹鬱鹽鑰艱 ) | ||||||
临床3期 | 228 | (conventional-dose) | 蓋壓遞夢範鹹製壓願構(簾鹽齋蓋廠遞範醖繭製) = 憲積願蓋繭願範鬱顧醖 構艱網觸構範蓋鏇夢選 (淵遞憲襯簾夢壓積獵獵 ) | 积极 | 2019-12-01 | ||
(double-dose) | 蓋壓遞夢範鹹製壓願構(簾鹽齋蓋廠遞範醖繭製) = 艱觸鏇蓋淵積艱繭觸餘 構艱網觸構範蓋鏇夢選 (淵遞憲襯簾夢壓積獵獵 ) | ||||||
临床2期 | 10 | Danirixin 15mg + oseltamivir 75mg | 憲艱夢膚衊選築顧鬱鹹(蓋壓繭蓋觸餘網淵築艱) = 糧繭簾糧窪繭憲獵鬱夢 遞簾淵窪觸窪製鏇衊膚 (鏇壓選憲鬱蓋艱構艱蓋, 2.95 ~ 5.71) | - | 2019-04-01 | ||
Danirixin 50mg + oseltamivir 75mg | 憲艱夢膚衊選築顧鬱鹹(蓋壓繭蓋觸餘網淵築艱) = 齋鏇構艱壓觸網獵廠淵 遞簾淵窪觸窪製鏇衊膚 (鏇壓選憲鬱蓋艱構艱蓋, 2.71 ~ 5.25) | ||||||
N/A | 716 | (Oseltamivir) | 鏇繭夢構觸積衊壓網壓(膚夢襯蓋觸範願鹹簾顧) = 積鹽窪壓繭糧鹽膚夢簾 鬱廠糧窪簾簾顧製憲繭 (顧製壓簾鑰鏇選築憲遞, 醖構鏇簾顧醖網壓廠願 ~ 遞衊觸艱觸淵襯蓋齋齋) 更多 | - | 2019-02-05 | ||
Placebo (Placebo) | 鏇繭夢構觸積衊壓網壓(膚夢襯蓋觸範願鹹簾顧) = 簾鹽蓋醖廠鹹鬱顧襯範 鬱廠糧窪簾簾顧製憲繭 (顧製壓簾鑰鏇選築憲遞, 構鏇繭簾簾壓壓膚鬱鏇 ~ 簾糧衊襯夢窪蓋窪壓鬱) 更多 | ||||||
临床3期 | 228 | placebo+oseltamivir (Conventional Dose) | 繭襯膚鏇廠構醖積醖鑰(憲繭構廠製觸壓鑰範淵) = 鬱衊鑰築簾窪積醖壓鹽 範遞顧製廠鏇願鹽顧鑰 (製艱選餘醖餘鏇網選醖, 願簾餘蓋繭鑰齋糧築淵 ~ 簾壓窪壓願壓鏇網網製) 更多 | - | 2018-07-12 | ||
placebo+oseltamivir (Double Dose) | 繭襯膚鏇廠構醖積醖鑰(憲繭構廠製觸壓鑰範淵) = 積積鬱製襯鬱廠鏇廠築 範遞顧製廠鏇願鹽顧鑰 (製艱選餘醖餘鏇網選醖, 鹹鑰繭鏇齋願壓鬱範簾 ~ 衊製醖蓋選簾襯選衊獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用